Chicago Capital Doubles Down on PRCT

Chicago Capital has significantly increased its investment in PROCEPT BioRobotics, now holding a 1.46% stake worth $54 million, following a SEC filing. Despite PRCT shares dropping by 56.5% over the past year, Chicago Capital has been buying the stock for seven out of the last eight quarters. PRCTs AquaBeam Robotic System, used for minimally invasive prostate surgery, has seen a surge in procedure counts and installed base, with improved margins. The company is now recommended by European urologists and trades at a low 4.2 times sales, presenting a high-volatility opportunity for investors. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1779b6e6db0bd360